Drug Profile


Alternative Names: Anti-FGF 23 monoclonal antibody; Anti-fibroblast growth factor 23 monoclonal antibody; KRN-23; UX 023

Latest Information Update: 21 Apr 2017

Price : $50

At a glance

  • Originator Kyowa Hakko Kirin
  • Developer Kyowa Hakko Kirin; Ultragenyx Pharmaceutical
  • Class Monoclonal antibodies
  • Mechanism of Action Fibroblast growth factor 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - X-linked dominant hypophosphataemic rickets
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration X-linked dominant hypophosphataemic rickets
  • Phase II Nevus; Osteomalacia

Most Recent Events

  • 18 Apr 2017 Efficacy and adverse events data from a phase III trial in X-linked dominant hypophosphataemic rickets released by Ultragenyx Pharmaceutical
  • 16 Feb 2017 Ultragenyx announces intention to submit BLA to the USFDA in the second quarter of 2017
  • 05 Jan 2017 European Medicines Agency accepts MAA for X-linked dominant hypophosphataemic rickets (In adults, In children, In infants) for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top